Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

ConditionsAcute Myeloid Leukemia (AML)Chronic Myeloid Leukemia Myelodysplastic Syndromes (MDS)Myeloprolipherative Neoplsm Atypical Chronic Myeloid Leukemia

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-70

SponsorSt. Petersburg State Pavlov Medical University

About this trial

Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD

Eligibility criteria

Qualifiers

Patients with indication for allogeneic hematopoietic stem cell transplantation

Patients with <10/10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.

Peripheral blood stem cells or bone marrow as a graft source

Disqualifiers

Patients with indication for allogeneic hematopoietic stem cell transplantation

Patients with <10/10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.

Peripheral blood stem cells or bone marrow as a graft source

Trial design

Treatments tested in this trial

Ruxolitinib
Abatacept (Orencia)

Treatment groups

60 Participants

are divided into 3 treatment groups

Sponsors and collaborators

St. Petersburg State Pavlov Medical University

Lead sponsor

Source ClinicalTrials.gov